BGB A333

Drug Profile

BGB A333

Alternative Names: BGB-A333

Latest Information Update: 29 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BeiGene
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD274 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 29 Dec 2017 Beigene has patent protection for BGB A333 (WO2016161960 A1)
  • 23 Nov 2017 Phase-I/II clinical trials in Solid tumours (Combination therapy, Second-line therapy or greater, Late-stage disease, Metastatic disease) in Australia (Parenteral) (NCT03379259)
  • 23 Nov 2017 Phase-I/II clinical trials in Solid tumours (Monotherapy, Second-line therapy or greater, Late-stage disease, Metastatic disease) in Australia (Parenteral) (NCT03379259)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top